This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Connetics Gets Bad News From FDA

Shares of Connetics (CNCT) were sinking in premarket trading Monday after the company said the Food and Drug Administration issued a nonapprovable letter for Velac Gel, an investigational new drug formulation for treating acne.

The company said the only issue raised in the letter was a positive carcinogenicity signal that was detected in a mouse study. Connetics, a specialty pharmaceutical company focused on dermatology, saw its shares slide $4.27, or 21%, to $16.50 before the opening bell.

As a result of the FDA decision, Connetics now projects 2005 total revenue of $182 million to $188 million, down from its previous guidance of $195 million to $206 million. Earnings will likely be 66 cents to 70 cents a share, vs. the prior outlook of 88 cents to 92 cents a share.

"We remain committed to bringing Velac to market, and will be working with FDA representatives to determine what is required to do so," the company said in a press release. "Despite this setback, Connetics will continue to expand its leading position in the dermatology field with four brands on the market and a robust and diverse pipeline."

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
CNCT $0.01 0.00%
AAPL $130.28 0.47%
FB $81.53 -1.07%
GOOG $565.06 3.30%
TSLA $218.42 -0.08%

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs